Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss,…
Radisson to Participate in The Gentile Mining Investor Forum in London
3DG Jewellery Celebrates Its 23rd Anniversary in Dazzling Style
Enablence Technologies Inc. Closes C$25 Million Strategic Investment
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
TMD SPACE Launches ThailandCompanyDocs.com to Support Global Businesses Working with Thai Companies